Replimune Group (NASDAQ:REPL) Hits New 1-Year High – What’s Next?

Replimune Group, Inc. (NASDAQ:REPL) reached a new 52-week high during trading on Monday. The company traded as high as $22.22 and last traded at $22.4440, with a volume of 248,937 shares changing hands. The stock had previously closed at $21.62.

Analysts Set New Price Targets

Several research firms have recently commented on REPL. Piper Sandler upgraded shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a report on Friday, July 31st. Wolfe Research upgraded shares of Replimune Group to an “outperform” rating in a research note on Tuesday, August 4th. Wall Street Zen raised shares of Replimune Group from a “sell” rating to a “hold” rating in a report on Saturday, October 31st. Weiss Ratings reissued a “sell (e+)” rating on shares of Replimune Group in a research note on Wednesday, November 4th. Finally, Leerink Partners upped their target price on Replimune Group from $19.00 to $31.00 and gave the stock an “outperform” rating in a report on Thursday, October 29th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $14.33.

Replimune Group Stock Up 4.6%

The firm has a market capitalization of $2.21 billion, a P/E ratio of -8.34 and a beta of 0.93. The company has a debt-to-equity ratio of 0.59, a quick ratio of 6.90 and a current ratio of 7.11. The business’s fifty day moving average price is $14.39 and its two-hundred day moving average price is $9.82.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings data on Wednesday, October 28th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.24. Equities analysts expect that Replimune Group, Inc. will post -2.40 earnings per share for the current fiscal year.

Insider Transactions at Replimune Group

In other news, CFO Emily Hill sold 9,256 shares of the firm’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $14.28, for a total value of $132,175.68. Following the completion of the sale, the chief financial officer owned 215,852 shares of the company’s stock, valued at $3,082,366.56. This trade represents a 4.11% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Joseph P. Slattery sold 5,200 shares of the firm’s stock in a transaction on Monday, November 9th. The stock was sold at an average price of $21.80, for a total value of $113,360.00. Following the completion of the sale, the director directly owned 1,467 shares of the company’s stock, valued at $31,980.60. The trade was a 78.00% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 35,956 shares of company stock valued at $654,036. Corporate insiders own 5.40% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Essential Partners LLC boosted its holdings in Replimune Group by 562,400.0% in the first quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock worth $43,000 after acquiring an additional 5,624 shares in the last quarter. Allworth Financial LP acquired a new position in shares of Replimune Group during the second quarter valued at about $62,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Replimune Group during the third quarter valued at about $64,000. Legal & General Group Plc purchased a new position in shares of Replimune Group in the 2nd quarter valued at approximately $85,000. Finally, WINTON GROUP Ltd purchased a new position in shares of Replimune Group in the 2nd quarter valued at approximately $115,000. 92.53% of the stock is currently owned by hedge funds and other institutional investors.

Replimune Group Company Profile

Replimune Group is a biotechnology company focused on developing tumor-directed immunotherapies for people with cancer. Its proprietary platform uses genetically modified herpes simplex viruses, designed to be injected into tumors and stimulate an immune response against cancer. The company’s investigational pipeline includes RP1, an engineered oncolytic virus that expresses proteins intended to promote tumor cell destruction and immune activation. Replimune is also developing other candidates that combine virus-based treatment with additional immune-stimulating approaches.